These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33408020)

  • 1. Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
    Goldman JD; Diaz G; Urba WJ
    Int J Antimicrob Agents; 2021 Jan; 57(1):106174. PubMed ID: 33408020
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
    Saad MO
    Int J Antimicrob Agents; 2021 Jan; 57(1):106171. PubMed ID: 33408024
    [No Abstract]   [Full Text] [Related]  

  • 3. Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.
    Dos Santos MR
    Int J Antimicrob Agents; 2021 Jan; 57(1):106176. PubMed ID: 33408022
    [No Abstract]   [Full Text] [Related]  

  • 4. Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
    Wambier CG
    Int J Antimicrob Agents; 2021 Jan; 57(1):106175. PubMed ID: 33408021
    [No Abstract]   [Full Text] [Related]  

  • 5. Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.
    Nguyen TV
    Int J Antimicrob Agents; 2021 Jan; 57(1):106169. PubMed ID: 33408026
    [No Abstract]   [Full Text] [Related]  

  • 6. Can we use hydroxychloroquine to treat COVID-19 now?
    Chen J; Liu D; Yin L; Zhang L; Lu H
    Int J Antimicrob Agents; 2021 Jan; 57(1):106173. PubMed ID: 33408016
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.
    Gautret P; Honoré S; Lagier JC; Raoult D
    Int J Antimicrob Agents; 2021 Jan; 57(1):106236. PubMed ID: 33408025
    [No Abstract]   [Full Text] [Related]  

  • 8. Advanced statistical methods and designs for clinical trials for COVID-19.
    Shan G; Wang W
    Int J Antimicrob Agents; 2021 Jan; 57(1):106167. PubMed ID: 33408032
    [No Abstract]   [Full Text] [Related]  

  • 9. Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality.
    De Schryver N; Serck N; Vinetti M; Gérard L
    Int J Antimicrob Agents; 2021 Jan; 57(1):106254. PubMed ID: 33259917
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
    Parra-Lara LG; Martinez-Arboleda JJ; Isaza-Pierotti DF; Rosso F
    Int J Antimicrob Agents; 2021 Jan; 57(1):106172. PubMed ID: 33408017
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
    Million M; Roussel Y; Gautret P; Raoult D
    Int J Antimicrob Agents; 2021 Jan; 57(1):106240. PubMed ID: 33408019
    [No Abstract]   [Full Text] [Related]  

  • 12. Doxycycline as an Alternative to Azithromycin in Elderly Patients.
    Malek AE; Granwehr BP
    Int J Antimicrob Agents; 2021 Jan; 57(1):106168. PubMed ID: 33408018
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.
    Gautret P; Lagier JC; Honoré S; Hoang VT; Raoult D
    Int J Antimicrob Agents; 2021 Jan; 57(1):106242. PubMed ID: 33408033
    [No Abstract]   [Full Text] [Related]  

  • 14. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.
    Gautret P; Lagier JC; Honoré S; Hoang VT; Colson P; Raoult D
    Int J Antimicrob Agents; 2021 Jan; 57(1):106243. PubMed ID: 33408014
    [No Abstract]   [Full Text] [Related]  

  • 15. Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19.
    Colson P; La Scola B; Lagier JC; Gautret P; Raoult D
    Int J Antimicrob Agents; 2021 Jan; 57(1):106238. PubMed ID: 33408030
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes.
    Gautret P; Hoang VT; Lagier JC; Raoult D
    Int J Antimicrob Agents; 2021 Jan; 57(1):106239. PubMed ID: 33408029
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.
    Fiolet T; Guihur A; Rebeaud ME; Mulot M; Peiffer-Smadja N; Mahamat-Saleh Y
    Clin Microbiol Infect; 2021 Jan; 27(1):19-27. PubMed ID: 32860962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxychloroquine (HCQ): real treatment or false hope?
    El Bakkouri K
    Int J Antimicrob Agents; 2021 Jan; 57(1):106170. PubMed ID: 33408023
    [No Abstract]   [Full Text] [Related]  

  • 19. QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
    Wu TC; Sacilotto L; Darrieux FCDC; Pisani CF; Melo SL; Hachul DT; Scanavacca M
    Arq Bras Cardiol; 2020 Jun; 114(6):1061-1066. PubMed ID: 32638906
    [No Abstract]   [Full Text] [Related]  

  • 20. Usefulness and safety of self-electrocardiographic monitoring during treatment with hydroxychloroquine and azithromycin in COVID-19 patients.
    García-Fernández A; Ramos-Ruiz P; Ibáñez-Criado A; Moreno-Pérez Ó; Cambra-Poveda C; Martínez-Martínez JG;
    Rev Esp Cardiol (Engl Ed); 2021 Jan; 74(1):108-111. PubMed ID: 33077410
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.